Alteplase

Alteplase dosing may be weight based; ensure accuracy of documented weight before administration	
Potential SALAD Actilyse® is used for systemic thrombolysis. Do not confuse with Actilyse Cathflo® used for thrombolytic treatment of occluded central venous access devices.	
CAUTION: High Administration Risk Rating	
Form	50mg vial powder for solution for injection + 50mL solvent (WFI) 20mg vial powder for solution for injection + 20mL solvent (WFI) 10mg vial powder for solution for injection + 10mL solvent (WFI)
Reconstitution	Add 50mL solvent to 50mg vial (final concn 1mg/mL) Add 20mL solvent to 20mg vial (final concn 1mg/mL) Add 10mL solvent to 10mg vial (final concn 1mg/mL) • Agitate gently until all powder dissolved. • DO NOT SHAKE. If there are bubbles, let the solution stand undisturbed for a few minutes to allow them to disappear
Compatibility & Stability	Sodium chloride 0.9% Reconstituted solutions should be used immediately but are stable in the fridge for 24hrs or for 8hrs at room temperature (<25°C)
Administration	**IV bolus**, followed by **IV infusion** (intermittent) The reconstituted solution may be diluted further with sodium chloride 0.9% to a minimal concentration of 200micrograms in 1mL. Do not dilute with glucose 5%. **IV infusion**: varying lengths and doses based on indication and weight, usually up to a maximum of three hours.
	See tables for PE and Acute Stroke **Refer to Product Literature to determine dose and infusion times for other indications**
Monitoring	• ECG and BP monitoring recommended
Additional Information	• Treatment should be initiated as soon as possible after symptom onset. • Actilyse® should not be administered to patients with a known hypersensitivity to Gentamicin (trace residue from manufacturing process). • Standard resuscitation equipment & pharmacotherapy should be available. • Dilution to less than 200mcg/mL is not recommended. • **SALAD**: Do not confuse Actilyse ® with Actilyse Cathflo® used for thrombolytic treatment of occluded central venous access devices.

Information provided relates to Actilyse manufactured by Boehringer Ingelheim

Alteplase for Treatment of Pulmonary Embolism

Using alteplase with concentration of 1mg/ml

1. Administration of Alteplase for PE should be sanctioned by either a consultant or registrar
2. Dose (>65kg): 10mg as IV bolus over 1-2 mins, followed by 90mg as IV infusion over 2hrs
3. In patients <65kg, total dose should not exceed 1.5mg/kg
4. Maximum dose is 100mg

Body Weight (kg)	Total Dose (mg)	Initial bolus (mg) (1-2mins)	IV infusion Dose (mg) (2 hours)	Infusion rate (mL/hr)
40	60	10	50	25
42	63	10	53	26.5
44	66	10	56	28
46	69	10	59	29.5
48	72	10	62	31
50	75	10	65	32.5
52	78	10	68	34
54	81	10	71	35.5
56	84	10	74	37
58	87	10	77	38.5
60	90	10	80	40
62	93	10	83	41.5
64	96	10	86	43
66	100	10	90	45
68	100	10	90	45
70	100	10	90	45
72	100	10	90	45
74	100	10	90	45
76	100	10	90	45
78	100	10	90	45
80	100	10	90	45
82	100	10	90	45
84	100	10	90	45
86	100	10	90	45
88	100	10	90	45
90	100	10	90	45
92	100	10	90	45
94	100	10	90	45
96	100	10	90	45
98	100	10	90	45
100	100	10	90	45

Alteplase for Treatment of Acute Stroke

Using alteplase with concentration of 1mg/ml
The recommended total dose is 0.9 mg alteplase/kg body weight (maximum of 90 mg) starting with 10% of the total dose as an initial intravenous bolus, immediately followed by the remainder of the total dose infused intravenously over 60 minutes

Body Weight (kg)	Total Dose (mg)	Initial bolus (mg) (1-2mins)	IV infusion Dose (mg) (1 hour)	Infusion rate (mL/hr)
40	36.0	3.6	32.4	32.4
42	37.8	3.8	34.0	34.0
44	39.6	4.0	35.6	35.6
46	41.1	4.1	37.3	37.3
48	43.2	4.3	38.9	38.9
50	45.0	4.5	40.5	40.5
52	46.8	4.7	42.1	42.1
54	48.6	4.9	43.7	43.7
56	50.4	5.0	45.4	45.4
58	52.2	5.2	47.0	47.0
60	54.0	5.4	48.6	48.6
62	55.8	5.6	50.2	50.2
64	57.6	5.8	51.8	51.8
66	59.4	5.9	53.5	53.5
68	61.2	6.1	55.1	55.1
70	63.0	6.3	56.7	56.7
72	64.8	6.5	58.3	58.3
74	66.6	6.7	59.9	59.9
76	68.4	6.8	61.6	61.6
78	70.2	7.0	63.2	63.2
80	72.0	7.2	64.8	64.8
82	73.8	7.4	66.4	66.4
84	75.6	7.6	68.0	68.0
86	77.4	7.7	69.7	69.7
88	79.2	7.9	71.3	71.3
90	81.0	8.1	72.9	72.9
92	82.8	8.3	74.5	74.5
94	84.6	8.5	76.1	76.1
96	86.4	8.6	77.8	77.8
98	88.2	8.8	79.4	79.4
100 +	90.0	9.0	81.0	81.0

Alteplase (Cathflo®)

Potential SALAD Actilyse Cathflo® is used for thrombolytic treatment of occluded central venous access devices. Do not confuse Actilyse Cathflo® with Actilyse® used for systemic thrombolysis.		
Form & Storage	2mg powder for solution for injection	Store in a refrigerator at 2–8°C
Reconstitution	Reconstitute with 2.2mL water for injections to give a concentration of 1mg in 1mL (2mg in 2mL). Swirl the vial gently to avoid foam formation until contents are completely dissolved.	
Compatibility & Stability	Sodium Chloride 0.9%	
Administration	The reconstituted preparation is a clear and colourless to pale yellow solution. Prior to administration it should be inspected visually for particles and colour. Instil the appropriate volume of reconstituted solution into the occluded central venous access device.	

Device	Volume of Alteplase
PICC	1mL
Hickmann's	1 - 2mL
Port	1 - 2mL

- After at least 30 minutes of dwell time, assess catheter function by attempting to aspirate blood. If the catheter is still not functional, leave the alteplase in the catheter for a further 90 minutes (120 minutes total) and then try to aspirate blood and catheter contents.
- If catheter function is not restored after the first dose, a second dose of equal amount may be instilled. Repeat the procedure. If after a second dose of alteplase the device remains dysfunctional seek specialist advice.
- If catheter function has been restored, aspirate 4 - 5 mL of blood to remove alteplase and residual clot, and gently irrigate the catheter with Sodium Chloride 0.9%.

Additional Information	• Actilyse® should not be administered to patients with a known hypersensitivity to Gentamicin (trace residue from manufacturing process).

Information provided relates to Actilyse Cathflo® manufactured by Boehringer Ingelheim.